Parexel reports "new normal" in US drug review process
This article was originally published in SRA
There are "notable declines" in the US in first-cycle approval rates for priority drug applications and priority designation rates for new drugs, according to a new white paper from Parexel International's consulting arm1.
You may also be interested in...
Perhaps only a man who inherited an enthusiasm for peptides could, without a trace of irony, cast diabetes drug development as the work of a pastry chef. But for David Solomon, the son of a peptide devotee, mixed metaphors and stretched comparisons are simply the spray thrown up by his unbridled enthusiasm for his chosen trade, that of basketball coach to GLP-1 receptor agonist developer Zealand Pharma.
"How the hell will Glaxo need you? You've only got a few people, they've got about 50,000!"